Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)

NCT07123454 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07123454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07123454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 24, 2025
Completion date
March 1, 2028
Enrollment
91 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma